The human papillomavirus …show more content…
The prevention comes in two different vaccines, the first being Gardasil and the other being Cervarix. Ultimately, both vaccines surve the same purpose, but there is an advantage to receiving the Gardasil vaccine. The advantage is that it adds an additional layer of protection for HPV strains 6 and 11, which are commonly associated with condyloma. The goal for the vaccine is that it should be administered to girls between the ages of 11-12, hopefully before sexual activity begins. The vaccine comes in three doses and those receiving the dosage, should start to develop antibodies (Pandhi, 2011). If someone vaccinated, ever comes into contact with the human papillomavirus, the hope if that those antibodies would step forward and attack the virus before it can turn into anything more serious. The first series of vaccination should start when a physician suggests it. After the first does, at least four to eight weeks should go by before administering the second dosage. Depending on when the second dosage is taken, another twelve to sixteen weeks should be waited before receiving the final vaccination in the series. In situations where interventions are not already accessible, the option of having a preventional tool is highly sought out. Especially having the HPV vaccines where pre-cancer lesion screenings is not as organized (Garnett, 2014). Along …show more content…
When addressing the cost effectiveness of a vaccine, it is important to look at why people are choosing to receive this particular vaccine. For the HPV vaccine, the reason for many people to receive the vaccine is due to disease leading to mortality. These result greatly impact people’s choices on whether or not they receive the vaccine. In some cases, people see the vaccine as a blessing and a preventative step, while others see the vaccine as unnecessary introduction to a virus they may never com across in their life time. “In 2005, there were about 500,000 cases of cervical cancer and 260,000 related deaths worldwide. As per an estimate, the global burden of cervical cancer by the year 2050 will be more than 1 million new cases every year. Cervical cancer incidence rates vary from 1 to 50 per 100,000 females; rates are highest in Latin America and the Caribbean, sub-Saharan Africa, and south-central and South-East Asia. In India, cervical cancer ranks number one among cancer in females with an annual incidence of more than 132,000 and around 740,00 deaths every year” (Pandhi, 2011). The statistics above are indeed frightening and it should be an eye opener to many debating whether of not the human papillomavirus vaccine is relevant. The reason people choose to not receive the vaccine isn’t only because of their fear of getting HPV. Instead, it is